3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof

A compound, or a pharmaceutically acceptable salt thereof, of Formula I:

• wherein:
• R1 and R2 are independently selected from the group consisting of H and halide;
• R3 is selected from the group consisting of -heteroaryl optionally substituted with 1-4 R6 and -heterocyclyl optionally substituted with 1-10 R7;
• R5 is selected from the group consisting of H, -heteroaryl optionally substituted with 1-4 R8, -heterocyclyl optionally substituted with 1-10 R9, and -aryl optionally substituted with 1-5 R10;
• each R6 is independently selected from the group consisting of halide, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R11, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 R11, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 R11, —(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R12, —(C2-4 alkenylene)pcarbocyclyl optionally substituted with 1-12 R12, —(C2-4 alkynylene)pcarbocyclyl optionally substituted with 1-12 R12, —(C1-4 alkylene)paryl optionally substituted with 1-5 R13, —(C2-4 alkenylene)paryl optionally substituted with 1-5 R13, —(C2-4 alkynylene)paryl optionally substituted with 1-5 R13, —NHC(═O)R14, —NR15R16, —(C1-6 alkylene)NR17R18, —(C2-6 alkenylene)NR17R18, —(C2-6 alkynylene)NR17R18, and —(C1-4 alkylene)pOR24;
• each R7 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
• each R8 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —OCH3, —CN, and —C(═O)R19;
• each R9 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —CN, and —OCH3;
• each R10 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —CN, —(C1-6 alkylene)pNHSO2R19, —(C2-6 alkenylene)pNHSO2R19, —(C2-6 alkynylene)pNHSO2R19, —NR15(C1-6 alkylene)NR15R16, —NR15(C2-6 alkenylene)NR15R16, —NR15(C2-6 alkynylene)NR15R16, —(C1-6 alkylene)pNR15R16, —(C2-6 alkenylene)pNR15R16, —(C2-6 alkynylene)pNR15R16, and —OR27;
• each R11 is independently selected from the group consisting of amino, —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
• each R12 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
• each R13 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
• each R14 is independently selected from the group consisting of —(C1-9 alkyl), —(C1-4 haloalkyl), —(C2-9 alkenyl), —(C2-9 alkynyl), -heteroaryl optionally substituted with 1-4 R20, -aryl optionally substituted with 1-5 R21, —CH2aryl optionally substituted with 1-5 R21, -carbocyclyl optionally substituted with 1-12 R22, —CH2carbocyclyl optionally substituted with 1-12 R22, —(C1-4 alkylene)pNR25R26, —(C2-4 alkenylene)pNR25R26, —(C2-4 alkynylene)pNR25R26, -heterocyclyl optionally substituted with 1-10 R23, and —CH2heterocyclyl optionally substituted with 1-10 R23;
• each R15 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
• each R16 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —CH2aryl optionally substituted with 1-5 R21, and —CH2carbocyclyl optionally substituted with 1-12 R22;
• each R17 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
• each R18 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —CH2aryl optionally substituted with 1-5 R21, and —CH2carbocyclyl optionally substituted with 1-12 R22;
• each R19 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
• each R20 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
• each R21 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
• each R22 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
• each R23 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
• R24 is selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 R23, —(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R22, —(C2-4 alkenylene)pcarbocyclyl optionally substituted with 1-12 R22, —(C2-4 alkynylene)pcarbocyclyl optionally substituted with 1-12 R22, —(C1-4 alkylene)paryl optionally substituted with 1-5 R21, —(C2-4 alkenylene)paryl optionally substituted with 1-5 R21, —(C2-4 alkynylene)paryl optionally substituted with 1-5 R21, —(C1-6 alkylene)pNR25R26, —(C2-4 alkenylene)pNR25R26, and —(C2-4 alkynylene)pNR25R26;
• each R25 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
• each R26 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
• R27 is selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 R23, —(C1-6 alkylene)pNR25R26, —(C2-6 alkenylene)pNR25R26, and —(C2-6 alkynylene)pNR25R26;
• and
• each p is independently an integer of 0 or 1.